EHA Library - The official digital education library of European Hematology Association (EHA)

RELATIONSHIP BETWEEN PAKT1, PSYK PROTEINS CO-EXPRESSION AND SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA
Author(s):
Elena Vaneeva
,
Elena Vaneeva
Affiliations:
Laboratory of pathomorphology,The Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agency,Kirov,Russian Federation
Vitaliy Rosin
,
Vitaliy Rosin
Affiliations:
Laboratory of pathomorphology,The Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agency,Kirov,Russian Federation
Dmitry Diakonov
,
Dmitry Diakonov
Affiliations:
Laboratory of pathomorphology,The Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agency,Kirov,Russian Federation
Maksim Minaev
,
Maksim Minaev
Affiliations:
Laboratory of pathomorphology,The Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agency,Kirov,Russian Federation
Svetlana Samarina
Svetlana Samarina
Affiliations:
The Federal State-Financed Scientific Institution Kirov Research Institute of Hematology and Blood Transfusion under the Federal Medical Biological Agency,Kirov,Russian Federation
EHA Library. Vaneeva E. 06/09/21; 324126; PB1446
Elena Vaneeva
Elena Vaneeva
Contributions
PDF Abstract
Abstract

Abstract: PB1446

Type: Publication Only

Session title: Aggressive Non-Hodgkin lymphoma - Clinical

Background

 Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. The clinical criteria characterized by the International Prognostic Index (IPI) provide a standard model for risk stratification. However, there is variability in outcomes in IPI risk groups, which indicating the biological and clinical heterogeneity of the DLBCL and does not allow to accurately assess the individual risk of therapy failure. Development of the additional biological prognostic criteria of disease could allow to lower unfavorable outcome cases. Dysregulation of key molecules (pAKT1, pSyk) of the PI3K/AKT/mTOR and BCR signaling pathways involves the biological behavior of tumor cells and may affect on the course of DLBCL. It worth noting that monotypic overexpression of pAKT1 and pSyk is associated with low overall (OS) and progression-free (PFS) survival in DLBCL patients. Nevertheless, the combined

Aims
Assesment of relationship between co-expression pAKT1, pSyk proteins in tumor cells with OS and PFS in DLBCL. 

Methods

Abstract: PB1446

Type: Publication Only

Session title: Aggressive Non-Hodgkin lymphoma - Clinical

Background

 Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. The clinical criteria characterized by the International Prognostic Index (IPI) provide a standard model for risk stratification. However, there is variability in outcomes in IPI risk groups, which indicating the biological and clinical heterogeneity of the DLBCL and does not allow to accurately assess the individual risk of therapy failure. Development of the additional biological prognostic criteria of disease could allow to lower unfavorable outcome cases. Dysregulation of key molecules (pAKT1, pSyk) of the PI3K/AKT/mTOR and BCR signaling pathways involves the biological behavior of tumor cells and may affect on the course of DLBCL. It worth noting that monotypic overexpression of pAKT1 and pSyk is associated with low overall (OS) and progression-free (PFS) survival in DLBCL patients. Nevertheless, the combined

Aims
Assesment of relationship between co-expression pAKT1, pSyk proteins in tumor cells with OS and PFS in DLBCL. 

Methods

What's new at EHA

Browse the open-source material from EHA past Congresses and meetings.

References

EHA Terms & Conditions
2025 ©
European Hematology Association
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies